Monte Rosa Therapeutics Inc. Common Stock GLUE · Stock Open Monte Rosa Therapeutics Inc. Common Stock in new tab
Monte Rosa Therapeutics Inc. Common Stock Analysis (GLUE)
Is Monte Rosa Therapeutics Inc. Common Stock a good investment? Monte Rosa Therapeutics Inc. Common Stock (GLUE) is currently trading at 15.38 USD. Market analysts have a consensus price target of 30.67 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 49.25. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Monte Rosa Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.81.
Investor FAQ
Does Monte Rosa Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Monte Rosa Therapeutics Inc. Common Stock?
Monte Rosa Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.48.
Company Profile
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Community Discussion